26 results
8-K
EX-99.1
VIR
Vir Biotechnology Inc
22 Feb 24
Vir Biotechnology Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results
4:12pm
included $13.4 million of non-cash stock-based compensation expense. The decrease was primarily driven by the wind down of clinical studies involving VIR
8-K
EX-99.1
u2lilkejy 1kee
2 Nov 23
Vir Biotechnology Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:09pm
8-K
z6w8iphfs60
3 Oct 23
Entry into a Material Definitive Agreement
8:01am
S-3ASR
lgo6weyc5vn0yyz
10 Nov 20
Automatic shelf registration
5:13pm
DRS
EX-10.58
fbyun7u
23 Jun 20
Draft registration statement
12:00am
DRS
EX-10.56
s4diz2eq7wx1ya 8l11
23 Jun 20
Draft registration statement
12:00am